ZEALAND PHARMA A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 622.2 DKK | -0.04% |
|
-4.82% | +66.67% |
| May. 16 | Nordic Stocks Declined Thursday; Zealand Pharma Took Biggest Hit | DJ |
| May. 16 | Transcript : Zealand Pharma A/S, Q1 2024 Earnings Call, May 16, 2024 |
ETFs positioned on Zealand Pharma A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +4.77% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 1 M€ | 0.00% | - | |
| 0.00% | 29 M€ | -1.74% | - | |
| 0.00% | 146 M€ | -1.80% | - | |
| 0.00% | 25 M€ | -2.62% | - |
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-08-15
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
622.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+26.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +66.67% | 5.64B | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -3.11% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- ZEAL Stock
- Funds and ETFs Zealand Pharma A/S
